{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2026-02-06T12:37:23.764262+00:00",
  "news": [
    {
      "title": "Amgen Tops Buy Zone On Positive 2026 Outlook Amid Sharpening Obesity Focus - Investor's Business Daily",
      "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPY04tc01oNDhJT3JpTkxpcVk3eFA5MW9pcUFsMjcwTk93elBPbFJZbVJhVXNpS0phbDdFX0luODhDVjhLQzdSel9SWHlmZmh4UUNSNEZCS2hRVHlfbjI1eUN5aVlhdGkwWmRJWURXS21FM1ZGYnliSm5HczVWNmZrM2R5SQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMigwFBVV95cUxPY04tc01oNDhJT3JpTkxpcVk3eFA5MW9pcUFsMjcwTk93elBPbFJZbVJhVXNpS0phbDdFX0luODhDVjhLQzdSel9SWHlmZmh4UUNSNEZCS2hRVHlfbjI1eUN5aVlhdGkwWmRJWURXS21FM1ZGYnliSm5HczVWNmZrM2R5SQ?oc=5\" target=\"_blank\">Amgen Tops Buy Zone On Positive 2026 Outlook Amid Sharpening Obesity Focus</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investor's Business Daily</font>",
      "published": "2026-02-04T21:04:00+00:00",
      "source": "Investor's Business Daily"
    },
    {
      "title": "Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSTlDdjNlWEJBbE5UZ0Z2NnBQcTk4cXZaUTJTRTdpVGRvZ1MxbTBNUmtUclVXYkV0N2tNSTRWVzZoUTRZU1dVUk1kelNfYzdoYXVlLU5tX3NHbFlwc1hwcmR2QVJSamdNeHhxM2h0Sm1fYlFBNEhwdkdTc2xVVkdmcm9aVHBnT2lZRWpvVExHZWlWbDlJc3cyMkhRWFpDakFuak1v?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiowFBVV95cUxQSTlDdjNlWEJBbE5UZ0Z2NnBQcTk4cXZaUTJTRTdpVGRvZ1MxbTBNUmtUclVXYkV0N2tNSTRWVzZoUTRZU1dVUk1kelNfYzdoYXVlLU5tX3NHbFlwc1hwcmR2QVJSamdNeHhxM2h0Sm1fYlFBNEhwdkdTc2xVVkdmcm9aVHBnT2lZRWpvVExHZWlWbDlJc3cyMkhRWFpDakFuak1v?oc=5\" target=\"_blank\">Amgen resists FDA request to pull rare disease drug Tavneos from the market</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2026-02-04T12:55:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "Angitia raises $130M to advance bone-building bispecifics - Fierce Biotech",
      "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOcU9zYlBDZWJqTmlraDdhakJsdUJYc3J5VlAzMnhMMF9MQjZFNFhlaV9BRWZ4dkcxa3l4WFkxM1RFV1pXMTNac00wbVpnX2JXWml1blNlUWtDeHhDRTk5WjdKRlRWQ2JLUllZWmFjT1FITkxSSy1tWmtuSEZfM0Z1SlFqZDhudm9kTDBveUljWkI5SVc0LXNXd21KMlRJZDhw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMioAFBVV95cUxOcU9zYlBDZWJqTmlraDdhakJsdUJYc3J5VlAzMnhMMF9MQjZFNFhlaV9BRWZ4dkcxa3l4WFkxM1RFV1pXMTNac00wbVpnX2JXWml1blNlUWtDeHhDRTk5WjdKRlRWQ2JLUllZWmFjT1FITkxSSy1tWmtuSEZfM0Z1SlFqZDhudm9kTDBveUljWkI5SVc0LXNXd21KMlRJZDhw?oc=5\" target=\"_blank\">Angitia raises $130M to advance bone-building bispecifics</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>",
      "published": "2026-02-05T15:17:55+00:00",
      "source": "Fierce Biotech"
    },
    {
      "title": "Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive",
      "link": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNOXJjVlRweEFDdlFaZUtScWl2UFJkWWVHNzgzWXhkT3BPX2hjWjJqRGhpZVJuOW4tbUdoWlZWQURCcjY2ZndZakh5M2Y4eDhEVWRvb0NnaWkwV1lWbzNaNmxYNElnQXpVLW5fY0xtdXREbWhNa0JZd19JZnVBblNITzdzWnlEbUpLRTU0RkxWV0g3c0NP?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMilAFBVV95cUxNOXJjVlRweEFDdlFaZUtScWl2UFJkWWVHNzgzWXhkT3BPX2hjWjJqRGhpZVJuOW4tbUdoWlZWQURCcjY2ZndZakh5M2Y4eDhEVWRvb0NnaWkwV1lWbzNaNmxYNElnQXpVLW5fY0xtdXREbWhNa0JZd19JZnVBblNITzdzWnlEbUpLRTU0RkxWV0g3c0NP?oc=5\" target=\"_blank\">Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma Dive</font>",
      "published": "2026-02-04T14:59:19+00:00",
      "source": "BioPharma Dive"
    },
    {
      "title": "Amgen Q4 results beat Street estimates, company says patients need weight-loss options - Reuters",
      "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQSEhLZkpIbUJyQVJwbnZ5MEVNUkF2MDNUYXgwcVpHcEFFM1N6eFJFa1Q4aFAtdGNPczNGbk82N0Q0c2xlMFhwN0ItN3pMTHBzTkJCbVJPX3F2QnIxeVRjakVQalNmNDBzTU9hN1VrSmlEamU0a1dvYkQwcXhVNmVxaDZKa3J0VjhQNHVUWno2a1k5eEVkX1ZycFZDalUwTG9hVVFsbVlITldNdjNCVFlaMk1vdTVZZGJlQ2otZ1RDdkEtdkpCSlZRY2VqQkV0VGpaYkNILXk0dWM2VUJCdnc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQSEhLZkpIbUJyQVJwbnZ5MEVNUkF2MDNUYXgwcVpHcEFFM1N6eFJFa1Q4aFAtdGNPczNGbk82N0Q0c2xlMFhwN0ItN3pMTHBzTkJCbVJPX3F2QnIxeVRjakVQalNmNDBzTU9hN1VrSmlEamU0a1dvYkQwcXhVNmVxaDZKa3J0VjhQNHVUWno2a1k5eEVkX1ZycFZDalUwTG9hVVFsbVlITldNdjNCVFlaMk1vdTVZZGJlQ2otZ1RDdkEtdkpCSlZRY2VqQkV0VGpaYkNILXk0dWM2VUJCdnc?oc=5\" target=\"_blank\">Amgen Q4 results beat Street estimates, company says patients need weight-loss options</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Reuters</font>",
      "published": "2026-02-03T21:05:09+00:00",
      "source": "Reuters"
    },
    {
      "title": "Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Zacks Investment Research",
      "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOTUpVZGZUUy1Zb0Z0anFta2o0QVhmRHJ1WlVjUlcwV2JJRDBCekRIdjh6WlVmYkNjNDVIRnFFMGxjVkZJTlF2OFlVM2xEVzZvUDdnaEZ1aVZ2eVA2eG1jMlJsZkxuV2ptZjc2ZUYyeWg2MFZ5cVR4Zi0wdnpDNTU5S21ZQ0I0d1FuR0Q1d1ZnLXo?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMikAFBVV95cUxOTUpVZGZUUy1Zb0Z0anFta2o0QVhmRHJ1WlVjUlcwV2JJRDBCekRIdjh6WlVmYkNjNDVIRnFFMGxjVkZJTlF2OFlVM2xEVzZvUDdnaEZ1aVZ2eVA2eG1jMlJsZkxuV2ptZjc2ZUYyeWg2MFZ5cVR4Zi0wdnpDNTU5S21ZQ0I0d1FuR0Q1d1ZnLXo?oc=5\" target=\"_blank\">Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Zacks Investment Research</font>",
      "published": "2026-02-04T18:39:55+00:00",
      "source": "Zacks Investment Research"
    },
    {
      "title": "Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (AMGN) - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOQXhvWE9TbW1KVjYxQzk2RHJpd1psWmgyQkdkN2tjaG8zbWRXclBoREpmbnhQS0U5c1BsTFc3djNfODZycHRFalhpbUNxVENPOXVhSS1pcy1UR2EzWGFhcDBqc1dXRTduMTJzT0U5d1VMYzlTVXJpVVM0enZqMEtab3dwc1FHNlNVdTZlR1k0NkxSM2hvZ2k2anU5NHk3ZXlrT1VDOTZTdlBxOGdBTTlXS2xTNmgyejQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMitwFBVV95cUxOQXhvWE9TbW1KVjYxQzk2RHJpd1psWmgyQkdkN2tjaG8zbWRXclBoREpmbnhQS0U5c1BsTFc3djNfODZycHRFalhpbUNxVENPOXVhSS1pcy1UR2EzWGFhcDBqc1dXRTduMTJzT0U5d1VMYzlTVXJpVVM0enZqMEtab3dwc1FHNlNVdTZlR1k0NkxSM2hvZ2k2anU5NHk3ZXlrT1VDOTZTdlBxOGdBTTlXS2xTNmgyejQ?oc=5\" target=\"_blank\">Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (AMGN)</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2026-02-04T12:55:40+00:00",
      "source": "Seeking Alpha"
    },
    {
      "title": "Amgen says it doesn’t plan to pull its rare disease drug Tavneos, despite FDA request - Endpoints News",
      "link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNNGpSdlU5aDU2QUZwY2ZrWGN2c1R1MjZsd1dIVkEzTTVEdk5SX3pMQ1U2eDhucjFUMFJvMmloOGppaFptdkpzVUhWWXBVYzBjdXFsN0FoMDN3eUtPSE1JdU0zVmYxRXZkMUZueEpkODJqdTJrY21LTzA2QmVnSnpjams5bTBmVm50ZThndGJGbmdic2tDX1owUg?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimAFBVV95cUxNNGpSdlU5aDU2QUZwY2ZrWGN2c1R1MjZsd1dIVkEzTTVEdk5SX3pMQ1U2eDhucjFUMFJvMmloOGppaFptdkpzVUhWWXBVYzBjdXFsN0FoMDN3eUtPSE1JdU0zVmYxRXZkMUZueEpkODJqdTJrY21LTzA2QmVnSnpjams5bTBmVm50ZThndGJGbmdic2tDX1owUg?oc=5\" target=\"_blank\">Amgen says it doesn’t plan to pull its rare disease drug Tavneos, despite FDA request</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Endpoints News</font>",
      "published": "2026-02-04T00:48:00+00:00",
      "source": "Endpoints News"
    }
  ],
  "product_launches": [
    {
      "title": "Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5\" target=\"_blank\">Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2026-02-04T03:18:16+00:00",
      "source": "TipRanks"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPWVRxV1RpY3FqQzcyYUVfWWhHYWtFRTI1NU5pM0VrOG5rRlRLbnhwbkhXd0VSWlZiVVRlNnNmOFdSd015dTktcUp6SGdDVHlySDdUeHp0ZWtSU3ZvQ0I0QkNIM20wVVpRdkQ3SHlPYkFBZWR1RncyaHdiSzBZMGJKMWt2NHdpZ0xLX0Y1endpNldSSUQtVlY0amVnMnZETm9JY2V6NHhseTdVTElacnpTaTJRQlo4dw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMitgFBVV95cUxPWVRxV1RpY3FqQzcyYUVfWWhHYWtFRTI1NU5pM0VrOG5rRlRLbnhwbkhXd0VSWlZiVVRlNnNmOFdSd015dTktcUp6SGdDVHlySDdUeHp0ZWtSU3ZvQ0I0QkNIM20wVVpRdkQ3SHlPYkFBZWR1RncyaHdiSzBZMGJKMWt2NHdpZ0xLX0Y1endpNldSSUQtVlY0amVnMnZETm9JY2V6NHhseTdVTElacnpTaTJRQlo4dw?oc=5\" target=\"_blank\">Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2025-12-19T08:00:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach - simplywall.st",
      "link": "https://news.google.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?oc=5",
      "summary": "<a href=\"https://news.google.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?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2025-09-08T07:00:00+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2026-02-05",
      "close": 367.79998779296875
    },
    "history": [
      {
        "date": "2026-01-28",
        "close": 342.2200012207031
      },
      {
        "date": "2026-01-29",
        "close": 342.94000244140625
      },
      {
        "date": "2026-01-30",
        "close": 341.8800048828125
      },
      {
        "date": "2026-02-02",
        "close": 344.67999267578125
      },
      {
        "date": "2026-02-03",
        "close": 338.5899963378906
      },
      {
        "date": "2026-02-04",
        "close": 366.20001220703125
      },
      {
        "date": "2026-02-05",
        "close": 367.79998779296875
      }
    ],
    "name": "Amgen Inc."
  }
}